BeyondSpring
  • About
    • Who We Are
    • Management Team
    • Scientific Advisors
    • Board of Directors
  • Pipeline & Research
    • Pipeline
    • Plinabulin
    • Protein Degradation
    • Other Pipeline
    • Posters & Publications
    • Collaborations
    • Expanded Access Policy
  • NEWS & MEDIA
  • Investors
    • Stock Overview
    • Events & Presentations
    • Financials & Filings
    • Corporate Governance
  • Careers
  • Contact Us
Select Page

ASCO

August 8, 2020

05.30.2020

American Society of Clinical Oncology (ASCO) Virtual Scientific Program (2020)

Head-to-Head Comparison of the Non-G-CSF Small Molecule Single Agent (SA) Plinabulin with SA Pegfilgrastim for the Prevention of Docetaxel Chemotherapy (Chemo)-Induced Neutropenia (CIN) in the PROTECTIVE-1 Trial

RECENT NEWS ARTICLES

  • BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
  • BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
  • BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
  • BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
  • BeyondSpring to Present at Two Upcoming Scientific Conferences in December
  • BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference
  • BeyondSpring Announces Pricing of Ordinary Shares
  • BeyondSpring Announces Proposed Public Offering of Ordinary Shares
  • BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates
  • BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia

RECENT MEDIA COVERAGE

  • New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
  • Seed Therapeutics blossoms in an $800M deal with Lilly
  • Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
  • BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
  • JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
  • Pegfilgrastim Plus Plinabulin Reduces Chemo-Induced Neutropenia in TAC-Treated Patients
  • Dr. Lan Huang Featured in Nature Titled “‘Innovation’ Nation”
  • Woman of the Week Podcast: Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer BeyondSpring
  • Developing Triple-Combination Immunotherapies: Lessons Learned From HIV
  • Meet BeyondSpring: A Fly exclusive interview with CEO Lan Huang

WORK WITH US

LifeSci Advisors
Investor Contact
Ashley R. Robinson
+1 617-430-7577
arr@lifesciadvisors.com
Media Contact
Darren Opland, Ph.D.
+1 646-627-8387
darren@lifescicomms.com

BeyondSpring Inc.
+1 (646) 305-6387
general@beyondspringpharma.com

GET UPDATES

Subscribe to BeyondSpring News & Media!

ABOUT

  • Who We Are
  • Management Team
  • Scientific Advisors
  • Board of Directors

PIPELINE & RESEARCH

  • Pipeline Overview
  • Plinabulin
  • Protein Degradation
  • Other Pipeline
  • Posters & Publications
  • Collaboration
  • Expanded Access Policy

INVESTORS

  • Stock Overview
  • Events & Presentations
  • Financials & Filings
  • Corporate Governance

CAREERS

  • Job Opportunities

NEWS & MEDIA

  • Press Releases
  • Media Coverage
BeyondSprings Inc LinkedIn   BeyondSprings Inc Twitter

BeyondSprings Inc LinkedIn      BeyondSprings Inc Twitter

©2021 BeyondSpring Inc. All rights reserved.   Privacy Notice   |   Terms of Use

We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.OkPrivacy policy